Menu

Disrupting ophthalmology: change Patients’ lives!

oeil2
seniors2
oeil3

Disrupting ophthalmology: change Patients’ lives!

oeil2
seniors2
oeil3
goute
Capture d’écran 2022-04-22 à 17.21.29

Over 10% of the population uses eyedrops every day1

and sometimes several times a day. In addition, it is estimated that approximately 15 million intraocular injections are performed every year for the treatment of retinal diseases.

Despite these treatments, approximately 1.3 million people worldwide become blind each year and another 36 million become severely visually impaired. The World Health Organization (WHO) estimates that a total of 1 billion people have lost their sight due to diseases for which treatments are currently available 2.

goute
Capture d’écran 2022-04-22 à 17.21.29

Over 10% of the population uses eyedrops every day1

and sometimes several times a day. In addition, it is estimated that approximately 15 million intraocular injections are performed every year for the treatment of retinal diseases.

Despite these treatments, approximately 1.3 million people worldwide become blind each year and another 36 million become severely visually impaired. The World Health Organization (WHO) estimates that a total of 1 billion people have lost their sight due to diseases for which treatments are currently available 2.

Over 10% of the population uses eyedrops every day1

and sometimes several times a day. In addition, it is estimated that approximately 15 million intraocular injections are performed every year for the treatment of retinal diseases.

Despite these treatments, approximately 1.3 million people worldwide become blind each year and another 36 million become severely visually impaired. The World Health Organization (WHO) estimates that a total of 1 billion people have lost their sight due to diseases for which treatments are currently available 2.

goute
Capture d’écran 2022-04-22 à 17.21.29

A clear lack of innovation in ophthalmic drug delivery Eye diseases are currently addressed only via 2 ways

For treating the front-of-the-eye, topical therapies (i.e. eye drops, gels, ointments…) display variable efficacy as it depends on users’ gestures and compliance. 

The poor yield of eye drops (<5% drug absorbed3) leads chronic patients (e.g. glaucoma) to apply them every day and lifelong.

The low absorption rate of eye drops also prevents them from treating the back-of-the-eye. 

Retinal diseases (e.g. AMD, DME) require highly invasive intra-ocular injections that can only be performed by ophthalmologists. These procedures, repeated several times a year, are painful and generate stress for patients.

The lack of innovation in ocular drug delivery is leading to the #1 Unmet Medical Need in Ophthalmology4: treatment non-adherence in nearly half of patients5, resulting in millions of people losing their sight2, despite the available and effective medications.

 

Homepage243005

Founded in 2020 by two entrepreneurs with a track record in the development of ophthalmic therapies, BIOPHTA aims to radically improve the efficacy of eye treatments by leveraging the first 7-day continuous microdosing pharmaceutical form.

Patients self-administer our dry mini-tablets, which instantly turn into a gel and adhere firmly to the eye surface. These non-invasive ocular inserts provide a controlled, low-dose drug release until the next application, occurring one week later.

The lack of innovation in ocular drug delivery is leading to the #1 Unmet Medical Need in Ophthalmology4: treatment non-adherence in nearly half of patients5, resulting in millions of people losing their sight2, despite the available and effective medications.

 

Founded in 2020 by two entrepreneurs with a track record in the development of ophthalmic therapies, BIOPHTA aims to radically improve the efficacy of eye treatments by leveraging the first 7-day continuous microdosing pharmaceutical form. Patients self-administer our dry mini-tablets, which instantly turn into a gel and adhere firmly to the eye surface. These non-invasive ocular inserts provide a controlled, low-dose drug release until the next application, occurring one week later.

Homepage243005

The lack of innovation in ocular drug delivery is leading to the #1 Unmet Medical Need in Ophthalmology4: treatment non-adherence in nearly half of patients5, resulting in millions of people losing their sight2, despite the available and effective medications.

 

Homepage243005

Founded in 2020 by two entrepreneurs with a track record in the development of ophthalmic therapies, BIOPHTA aims to radically improve the efficacy of eye treatments by leveraging the first 7-day continuous microdosing pharmaceutical form. Patients self-administer our dry mini-tablets, which instantly turn into a gel and adhere firmly to the eye surface. These non-invasive ocular inserts provide a controlled, low-dose drug release until the next application, occurring one week later.

Board of directors

Founding team

Jean droite_2805

Jean GARREC, Pharm D Founder & CEO

Jean holds a Pharm D. and an MBA with 20 years business experience in the field of ophthalmic industry. He gained an excellent understanding of the market, challenges, and players in eye pharmaceuticals. Jean held several general management experiences for building and steering companies, that provided him the required expertise in global business development, market access, and government price negotiations.

Jean gauche_2805

Jean CUINÉ, Pharm D, PhD Co-founder and CTO

Jean holds a Pharm.D., a Ph.D. in Pharmaceutical Sciences and an MBA. He has 20 years international experience and a track record developing new drugs from ideation to market. Jean started his career as a Research Scientist in drug delivery at Monash University prior to lead global development organizations and programs portfolio at executive level at Stallergenes Greer, Nextpharma, Cenexi and Novartis.

Non-executive Directors

boulay2_2805

Alexandre BOULAY, PhD GO Capital

Alexandre holds a PhD in Chemistry with a degree in chemisty applied to Life Sciences and a master in Corporate Finance. After several years in consulting then as a Technology Transfer Officer, he joined GO Capital in 2020 where he is currently Senior Associate serving on the board of several companies in Healthtech and Deeptech.

candela_2805

Valérie CALENDA, PhD Mérieux Equity Partners

Valérie holds a PhD in Pharmacology with a degree in Hematology and a B.Sc. in Biochemistry-Immunology. She is a former research scientist in Hematology and Virology at INSERM and then transitioned to Transgene (affiliate of Institut Mérieux) focusing on gene therapy and immunotherapy. Valérie joined Mérieux Equity Partners in January 2010 as Managing Partner, serving on the board of companies in Europe, Israel and North America.

denis_2805

Florian DENIS, MsC Elaia partners

Florian holds a MsC from Master MTI (Management of Technology and Innovation) – Université Paris Dauphine – Mines Paristech – ENS and Sup’Biotech Paris. He joined Elaia in 2019 and is an active member of the life sciences investments. He started his career in venture capital in 2015 at Auriga Partners. Florian serves on the Board of Directors of several companies and is responsible for the exit of Mablink Bioscience which was sold to Eli Lilly.

fleury_2805

Valentin T. FLEURY, MsC  HTL Biotechnology

Valentin obtained a MsC from Ecole Centrale Lyon. He was strategy consultant for healthcare and life sciences companies. As an advisor and board member, he has supported the development of numerous start-ups, notably in ophthalmology. During his various tenures he engaged several strategic alliances and M&A. He currently serves as Head of Strategy at HTL Biotechnology, where he adeptly conceived and led HTL’s diversification strategy.

masson_2805

Nathalie MASSON, Pharm D Unither pharmaceuticals

Nathalie holds a Pharm D. and an MSc in Process Engineering. She gained more than 30 years experience in pharmaceutical development at the global level for Rx pharmaceuticals, OTC, cosmetics and food supplements. Nathalie currently serves as the Director of Innovation and Development at Unither pharmaceuticals.

Our investors

ui_investissement blanc_2805
Logo_Merieux_Equity_Partners_highres blanc_2805
logo-elaia blanc_2805
go capital blanc_2805
unither blanc_2805
Logo_HTL2 blanc_2805

Our partners

France-Biotech
logo-Medicen-220 copie
bpi
ville de paris copie
Hello-Tomorrow copie
wilco copie
EIT-HEALTH-LOGO copie
ilab
inserm copie
CNRS copie
sorbone copie
Université_de_Lorraine
logo-cithefor copie
uni madrid2
  • Ref & notes
    1. Statista – Kantar Media 2021 UK study in 2020 on 24,024 respondents aged 15 years and older
    2. WHO publication, 2019 World Report on Vision
    3. Behar-Cohen et al.  – SFO report 2015
    4. Global Data report: Glaucoma Global Drug Forecast and Market Analysis to 2026
    5. Okeke et al.  – Ophthalmology Feb. 2009

Contact Us

BIOLABS Hôtel-Dieu | 8, rue Maria Helena Viera Da Silva, 75014 Paris - France
Le Biopôle | 6, rue Pierre Joseph Colin, 35000 Rennes - France
contact@biophta.com

    Contact Us

    BIOLABS Hôtel-Dieu | 8, rue Maria Helena Viera Da Silva, 75014 Paris - France
    Le Biopôle | 6, rue Pierre Joseph Colin, 35000 Rennes - France
    contact@test.usam.synology.me